Vaccine a success for human-to-human H5N1 case

A case of human-to-human transmission of bird flu has been confirmed in China, but authorities say it is another instance where the spread of the disease has been limited to a close blood relative. And in this case an experimental H5N1 vaccine demonstrated that it could possibly vanquish the lethal virus, which could have significant implications for the development of a pandemic vaccine.

A father caring for a sick son--who died--contracted the illness and was treated unsuccessfully with antivirals. Then he was given plasma drawn from a woman who had received an experimental bird flu vaccine that had been made from whole, killed H5N1. The vaccine was made by Sinovac from a 2004 Vietnamese strain of the disease. If researchers can show that the recovery was linked to the vaccine, the whole virus vaccine could prove a key to spurring immunity to a range of possible mutations of H5N1.

Late last year another bird flu patient in China recovered after being given plasma from a survivor of bird flu, pointing to the role that therapeutic antibodies could play in a fight against a potential pandemic.

- read the report in New Scientist
-
check out the story in the Independent

ALSO: Indian officials are fighting a fresh outbreak of H5N1 in birds. Report

Related Articles:
Sinovac to produce H5N1 vaccine. Report
Sinovac to mass produce bird flu vaccine. Report
GSK bird flu vaccine provides more positive data. Report

Suggested Articles

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.